Bright minds biosciences initiates dosing in phase i clinical trial of bmb-101 for dravet syndrome

In predictive animal models, bmb-101 demonstrated significant reduction in both the number and intensity of epileptic seizures in predictive animal models, bmb-101 demonstrated significant reduction in both the number and intensity of epileptic seizures
DRUG Ratings Summary
DRUG Quant Ranking